ANTIOXIDANT AND HYPOGLYCEMIC EFFECTS OF BROCCOLI (BRASSICA OLERACEA) ON OBESE DIABETIC RATS DOI Open Access
W. M. Hassan, Ahmed Ameen,

Eman El-Metwally

et al.

Egyptian Journal of Applied Science, Journal Year: 2023, Volume and Issue: 38(11), P. 53 - 68

Published: Nov. 1, 2023

The present work was aimed to investigate the possible antioxidant and hypoglycemic effects of broccoli on obese diabetic rats.Thirty adult male Sprague-Dawley rats were divided randomly into six equal groups (n=5) as follows: Group 1: negative control, fed a basal diet.Groups 2-6 High fat diet (HFD) for 6 weeks induce obesity.The then rendered by subcutaneous injection with single dose alloxan (120 mg/kg).Group 2 kept positive control group (obese rats) 3, 4, 5 HFDs-alloxan induced supplemented 2.5, 5, 7.5 10% dried broccoli.At end experiment, scarified serum collected biochemical analyses.The administration HFD-alloxan (control positive) resulted in significant elevations body weight gain, feed efficiency ratio, peritoneal pad, total cholesterol, triglyceride, LDL-c, VLDL-c, leptin, glucose, insulin, interleukin-1 beta malondialdehyde levels compared HDL-c glutathione peroxidase activity significantly decreased.On other hand, powder attenuated these adverse alterations caused administration.In conclusion, exhibits an hypolipidemic effective reducing glucose level rats.The study recommends that intake may be beneficial patients who suffer from diabetes obesity.

Language: Английский

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024 DOI Creative Commons
Harold Bays, Carol F. Kirkpatrick, Kevin C. Maki

et al.

Journal of clinical lipidology, Journal Year: 2024, Volume and Issue: 18(3), P. e320 - e350

Published: April 24, 2024

BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.

Language: Английский

Citations

27
Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024 DOI Creative Commons
Harold Bays, Carol F. Kirkpatrick, Kevin C. Maki

et al.

Obesity Pillars, Journal Year: 2024, Volume and Issue: 10, P. 100108 - 100108

Published: March 12, 2024

This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.

Language: Английский

Citations

19
Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023 DOI Creative Commons
Harold Bays,

Shagun Bindlish,

Tiffany Lowe Clayton

et al.

Obesity Pillars, Journal Year: 2023, Volume and Issue: 5, P. 100056 - 100056

Published: Jan. 28, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.

Language: Английский

Citations

32
Reframing interventions for optimal child nutrition and childhood obesity: the importance of considering psychological factors DOI Creative Commons
Lisa Newson, Julie Abayomi

Proceedings of The Nutrition Society, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 12

Published: Jan. 11, 2024

This review aims to emphasise the impact of poor nutrition on children's health and psychological well-being, urging those involved in childhood obesity or services broaden their intervention approach. Poor affect physical health. The stress living with further impacts quality life, well-being self-esteem. Children may experience adverse events stress, young people are able recall psychosocial issues such as experiencing stigma discrimination. Food is often a coping mechanism for managing negative emotions, perpetuating cycles emotional unhealthy eating behaviours. UK guidelines recommend family-based, multi-component weight management interventions children obesity. Interventions mainly target behaviours utilise behaviour change techniques attempting directly improve diet activity behavioural outcomes. Whilst these show some improvements there limited consideration understanding underlying mechanisms action which indirectly influence engagement sustainability change. Lack attention inclusion variables implementation help explain variable effectiveness reported across interventions. In conclusion, enhancing requires broader approach that fully incorporates factors. Those responsible commissioning, designing implementing should adopt holistic addresses needs while incorporating action. shift focus could result more sustainable comprehensive treatment

Language: Английский

Citations

9
Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023 DOI Creative Commons

Tiffany Lowe Clayton,

Angela Fitch, Harold Bays

et al.

Obesity Pillars, Journal Year: 2023, Volume and Issue: 8, P. 100083 - 100083

Published: Aug. 7, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides an overview of the mechanisms and treatment obesity hypertension.

Language: Английский

Citations

18
Obesity, thrombosis, venous disease, lymphatic disease, and lipedema: An obesity medicine association (OMA) clinical practice statement (CPS) 2023 DOI Creative Commons

Shagun Bindlish,

Jennifer Ng,

Wissam Ghusn

et al.

Obesity Pillars, Journal Year: 2023, Volume and Issue: 8, P. 100092 - 100092

Published: Oct. 19, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians with an overview on obesity, thrombosis, venous disease, lymphatic and lipedema.

Language: Английский

Citations

13
Semaglutide for weight loss: unanswered questions DOI Creative Commons
Ploutarchos Tzoulis, Stephanie Baldeweg

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: June 5, 2024

Citation: Tzoulis P and Baldeweg SE (2024) Semaglutide for weight loss: unanswered questions. Front. Endocrinol. 15:1382814. doi: 10.3389/fendo.2024.1382814

Language: Английский

Citations

4
Obesity Management in Primary Care: A Joint Clinical Perspective and Expert Review from the Obesity Medicine Association (OMA) and the American College of Osteopathic Family Physicians (ACOFP) - 2025 DOI Creative Commons
N. J. Pennings, Catherine Varney,

Stephanie L. Hines

et al.

Obesity Pillars, Journal Year: 2025, Volume and Issue: unknown, P. 100172 - 100172

Published: March 1, 2025

This collaboration from the Obesity Medicine Association (OMA) and American College of Osteopathic Family Physicians (ACOFP) examines obesity management a primary care perspective. joint perspective is based upon scientific evidence, clinical experience authors, peer review by OMA ACOFP leadership. The goal to identify answer sentinel questions about perspective, utilizing evidence-based publications, guided expert experience. disease that contributes both biomechanical complications most common cardiometabolic abnormalities encountered in care. Barriers impede optimal patients with include failure recognize as disease, lack accurate diagnosis, insufficient access treatment resources, inadequate training, time, adequate reimbursement adverse impact bias, stigma, discrimination. physicians are often first line healthcare setting. affords early intervention opportunities prevent and/or treat overweight obesity. Patient enhanced when clinicians risks benefits anti-obesity medications bariatric procedures, well long-term follow-up. Practical tools regarding 4 pillars nutrition therapy, physical activity, behavior modification, medical interventions (anti-obesity surgery) may assist improve health lives living

Language: Английский

Citations

0
Strategies to Address the Metabolic Burden of Psychotropic Medications DOI Creative Commons
Angelina Anthamatten, Queen Henry-Okafor

The Journal for Nurse Practitioners, Journal Year: 2025, Volume and Issue: 21(4), P. 105346 - 105346

Published: March 19, 2025

Language: Английский

Citations

0
Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review DOI Creative Commons
Harold Bays

Obesity Pillars, Journal Year: 2023, Volume and Issue: 7, P. 100076 - 100076

Published: June 13, 2023

A common adiposopathic complication of obesity is type 2 diabetes mellitus. Healthful weight reduction in patients with can improve glucose metabolism and potentially promote remission However, weight-reduction increased adiposity impaired among mellitus compared to without Data for this review were derived from PubMed appliable websites. Among body fat, the mechanisms underlying those are multifactorial, include energy conservation (i.e., improved control reduced glucosuria), hyperinsulinemia (commonly found many mellitus), potential use obesogenic anti-diabetes medications, contributions multiple systems. Other factors age, sex, genetic/epigenetic predisposition, environments. Even though impairs adiposity, clinically meaningful improves sometimes remission. An illustrative approach mitigate due choosing medications that increase insulin sensitivity loss deprioritize exposure gain.

Language: Английский

Citations

10